Drug-induced Torsades de Pointes in patients aged 80 years or more

Anadolu Kardiyoloji Dergisi

Volumn 8, Issue 4, 2008, Pages 260-265

  Paran, Yael ^a   Mashav, Noa ^a   Henis, Oren ^a   Swartzon, Michael ^a   Arbel, Yaron ^a   Justo, Dan ^a  

^a TEL AVIV UNIVERSITY   (Israel)

Author keywords

Nonagenarians; Octogenarians; Risk factors; Torsades de Pointes

Indexed keywords

AMIODARONE; AMITRIPTYLINE; ANTIARRHYTHMIC AGENT; ANTIHISTAMINIC AGENT; ASTEMIZOLE; CLARITHROMYCIN; ERYTHROMYCIN; FLUOXETINE; GATIFLOXACIN; HALOPERIDOL; IBUTILIDE; LEVOFLOXACIN; MACROLIDE; PSYCHOTROPIC AGENT; QUINIDINE; QUINOLONE DERIVATIVE; RISPERIDONE; ROXITHROMYCIN; SOTALOL; TERFANIDINE; TERODILINE;

ARTICLE; ATRIOVENTRICULAR BLOCK; CARDIOMYOPATHY; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; GERIATRIC CARE; HEART DISEASE; HEART LEFT VENTRICLE HYPERTROPHY; HEART VENTRICLE TACHYCARDIA; HUMAN; INCIDENCE; ISCHEMIC HEART DISEASE; QT INTERVAL; QT PROLONGATION; RISK FACTOR; SEX DIFFERENCE; SYSTEMATIC REVIEW; TORSADE DES POINTES;

AGED, 80 AND OVER; FEMALE; HUMANS; LONG QT SYNDROME; MACROLIDES; MALE; QUINOLONES; RISK FACTORS; SEX FACTORS; TORSADES DE POINTES;

EID: 50349100248     PISSN: 13028723     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (50)

1. Roden DM. Drug-induced prolongation of the QT interval. N Engl J Med 2004; 350: 1013-22.
2. Torp-Pedersen C, Moller M, Bloch-Thomsen PE, Kober L, Sandoe E, Egstrup K, et al. Dofetilide in patients with congestive heart failure and left ventricular dysfunction. N Engl J Med 1999; 341: 857-65.
3. Kannel WB, Pinsky JL: Trends in cardiac failure incidence and causes of three decades in the Framingham study. J Am Coll Cardiol 1991; 17: 87A.
4. Taylor SH. Diuretic therapy in congestive heart failure. Cardiol Rev 2000; 8: 104-14.
5. Kay GN, Plumb VJ, Arciniegas JG, Henthorn RW, Waldo AL. Torsades de pointes: the long-short initiating sequence and other clinical features: observations in 32 patients. J Am Coll Cardiol 1983; 2: 806-17.
6. Makkar RR, Fromm BS, Steinman RT, Meissner MD, Lehmann MH. Female gender as a risk factor for torsades de pointes associated with cardiovascular drugs. JAMA 1993; 270: 2590-7.
7. Wade OL. Drug therapy in the elderly. Age Ageing 1972; 1: 65-73.
8. Orimo H, Ito H, Suzuki T, Araki A, Hosoi T, Sawabe M, et al. Reviewing the definition of "elderly". Geriatrics & Gerontology International 2006; 6: 149-58.
9. Depp CA, Jeste DV. Definitions and predictors of successful aging: a comprehensive review of larger quantitative studies. Am J Geriatr Psychiatry 2006; 14: 6-20.
10. eMedicine: Atrial fibrillation. Available from: http://www.emedicine.com/ emerg/topic46.htm. Accessed on the 4th of June, 2007.
11. Arizona Center for Education and Research on Therapeutics. http://www.torsades.org/. Accessed on the 4th of June, 2007.
12. Napolitano C, Priori SG, Schwartz PJ. Torsades de pointes. Mechanisms and management. Drugs 1994; 47: 51-65.
13. eMedicine: Digitalis toxicity. Available from: http://www.emedicine.com/ med/topic568.htm. Accessed on the 4th of June, 2007.
14. Houltz B, Darpo B, Edvardsson N, Blomstrom P, Brachmann J, Crijns HJGM, et al. Electrocardiographic and clinical predictors of torsades de pointes induced by almokalant infusion in patients with chronic atrial fibrillation or flutter: a prospective study. Pacing Clin Electrophysiol 1998; 21: 1044-57.
15. Bazzet HC. An analysis of time relations of echocardiograms. Heart 1920; 7: 353-67.
16. Bertino JS Jr, Owens RC Jr, Carnes TD, Iannini PB. Gatifloxacin-associated corrected QT interval prolongation, torsades de pointes, and ventricular fibrillation in patients with known risk factors. Clin Infect Dis 2002; 34: 861-3.
17. Justo D, Mardi T, Zeltser D. Roxithromycin-induced torsades de pointes. Eur J Intern Med 2004; 15: 326-7.
18. Samaha FF. QTC interval prolongation and polymorphic ventricular tachycardia in association with levofloxacin. Am J Med 1999; 107: 528-9.
19. Fteha A, Fteha E, Haq S, Kozer L, Saul B, Kassotis J. Gatifloxacin induced torsades de pointes. Pacing Clin Electrophysiol 2004; 27: 1449-50.
20. Sekkarie MA. Torsades de pointes in two chronic renal failure patients treated with cisapride and clarithromycin. Am J Kidney Dis 1997; 30: 437-9.
21. Goss JE, Ramo BW, Blake K. Torsades de pointes associated with astemizole (Hismanal) therapy. Arch Intern Med 1993; 53: 2705.
22. Gitler B, Berger LS, Buffa SD. Torsades de pointes induced by erythromycin. Chest 1994; 105: 368-72.
23. Connolly MJ, Astridge PS, White EG, Morley CA, Cowan JC. Torsades de pointes ventricular tachycardia and terodiline. Lancet 1991; 338: 344-5.
24. Herrmann HC, Kaplan LM, Bierer BE. Q-T prolongation and torsades de pointes ventricular tachycardia produced by the tetracyclic antidepressant agent maprotiline. Am J Cardiol 1983; 51: 904-6.
25. Matsis PP, Easthope RN. Torsades de pointes ventricular tachycardia associated with terfenadine and paracetamol self medication. New Zeeland medical journal 1994; 369: 402-3.
26. McLeod AA, Thorogood S. Torsades de pointes complicating treatment with terodiline. Br Med J 1991; 302: 1469.
27. Ng KS, Tham LS, Tan HH, Chia BL. Cisapride and torsades de pointes in a pacemaker patient. Pacing Clin Electrophysiol 2000; 23: 130-2.
28. Rezkalla M, Pochop C. Erythromycin induced Torsades de Pointes: case report and review of the literature. S D J Med 1994; 47: 161-4.
29. Wilting I, Smals OM, Holwerda NJ, Meyboom RH, de Bruin ML, Egberts TC. QTc prolongation and torsades de pointes in an elderly woman taking fluoxetine. Am J Psychiatry 2006; 163: 325.
30. Tei Y, Morita T, Inoue S, Miyata H. Torsades de pointes caused by a small dose of risperidone in a terminally ill cancer patient. Psychosomatics 2004; 45: 450-1.
31. Voigt L, Coromilas J, Saul BI, Kassotis J. Amiodarone-induced Torsades de Pointes during bladder irrigation: an unusual presentation-a case report. Angiology 2003; 54: 229-31.
32. Gowda RM, Punukollu G, Khan IA, Patlola RR, Tejani FH, Cosme-Thormann BF, et al. Ibutilide-induced long QT syndrome and Torsades de Pointes. Am J Ther 2002; 9: 527-9.
33. Chou CC, Wu D. Torsades de pointes induced by metoclopramide in an elderly woman with preexisting complete left bundle branch block. Chang Gung Med J 2001; 24: 805-9.
34. Cammu G, Geelen P, Baetens P, De Vos J, Demeyer I. Two cases of torsades de pointes caused by sotalol therapy. Resuscitation 1999; 40: 49-51.
35. Dancey D, Wulffhart Z, McEwan P. Sotalol-induced torsades de pointes in patients with renal failure. Can J Cardiol 1997; 13: 55-8.
36. Gould LA, Betzu R, Vacek T, Muller RT, Pradeep V, Scafa A. Magnesium treatment of torsades de pointes: a case report. Angiology 1990; 41: 577-81.
37. Vorperian VR, Zhou Z, Mohammad S, Hoon TJ, Studenik C, January CT. Torsades de pointes with an antihistamine metabolite: potassium channel blockade with desmethylastemizole. J Am Coll Cardiol 1996; 28: 1556-61.
38. Carter JE Jr, Childers RW. Torsades de pointes complicating acute myocardial infarction: the importance of autonomic dysfunction as assessed by heart rate variability. Clin Cardiol 1992; 15: 769-72.
39. Kourgiannidis G, Chierchia GB, Wyffels E, Geelen P, Brugada P. A case of monomorphic ventricular tachycardia? J Cardiovasc Electrophysiol 2005; 16: 1014-16.
40. World population aging: 1950-2050. Available at: URL: http://www.un.org/ esa/population/publications/worldageing19502050/pdf/90chapteriv.pdf. Accessed on the 4th of June, 2007.
41. Vincent GM, Timothy KW, Leppert M, Keating M. The spectrum of symptoms and QT intervals in carriers of the gene for the long QT syndrome. N Engl J Med 1992; 327: 846-52.
42. Benton RE, Sale M, Flockhart DA, Woosley RL. Greater quinidine-induced QTc interval prolongation in women. Clin Pharmacol Ther 2000; 67: 413-18.
43. Tsuji Y, Opthof T, Kamiya K, Yasui K, Liu W, Lu Z, et al. Pacing-induced heart failure causes a reduction of delayed rectifier potassium currents along with decreases in calcium and transient outward currents in rabbit ventricle. Cardiovasc Res 2000; 48: 300-9.
44. Dupont H, Timsit JF, Souweine B, Gachot B, Wolff M, Regnier B. Torsades de pointes probably related to sparfloxacin. Eur J Clin Microbiol Infect Dis 1996; 15: 350-1.
45. Viskin S, Rosovski U, Sands AJ, Viskin S, Rosovski U, Sands AJ, et al. Inaccurate electrocardiographic interpretation of long QT: the majority of physicians cannot recognize a long QT when they see one. Heart Rhythm 2005; 2: 569-74.
46. Viskin S, Zelster D, Antzelevitch C. When u say "U Waves," what do u mean? Pacing Clin Electrophysiol 2004; 27: 145-7.
47. Allard J, Hébert R, Rioux M, Asselin J, Voyer L. Efficacy of a clinical medication review on the number of potentially inappropriate prescriptions prescribed for community-dwelling elderly people. CMAJ 2001; 164: 1291-6.
48. Curtis LH, Ostbye T, Sendersky V, Hutchison S, Allen LaPointe NM, Al-Khatib SM, et al. Prescription of QT-prolonging drugs in a cohort of about 5 million outpatients. Am J Med 2003; 114: 135-41.
49. Burkhart GA, Sevka MJ, Temple R, Honig PK. Temporal decline in filling prescriptions for terfenadine closely in time with those for either ketoconazole or erythromycin. Clin Pharmacol Ther 1997; 61: 93-6.
50. Torsades.org [Internet]. Tucson, Arizona and Rockville, Maryland, US: Arizona Center for Education and Research on Therapeutics The Critical Path Institute, [updated 2008 March 25]. Available from: http://www.torsades.org/.